
Advertise on podcast: From Models to Medicine
Rating
5from
This podcast has
30 episodes
Language
EnglishPublisher
KAMI Think TankExplicit
No
Date created
2026/03/13
Latest episode
2026/10/28
Average duration
36 min.
Release period
9 days
Description
At KAMI Think Tank, we love cutting through the AI hype to showcase where the technology actually stands and how to use it meaningfully within the life sciences. Now, we're bringing that same clarity with our community to a brand new podcast: From Models to Medicine. Every week, we sit down with a real practitioner in the life sciences, whether they're working in the lab, leading innovation at a biotech, or building tools to better serve scientists. We discuss how they cut through the hype of AI and practically leverage the tool in their scientific workflows. Glad to have you here.
Unlock From Models to Medicine podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from From Models to Medicine podcast
Episode 29: What Happens When You Build AI Around the Ovary
2026/10/28
In this episode of From Models to Medicine, we sit down with Mila Morris, founder and CEO of Nova Arc, who came to women's health not from medicine but from architecture and systems design. Mila noticed something in her regenerative medicine clinic where women were arriving with stacks of fragmented test results from multiple specialists and no coherent picture connecting any of it.
We get into why most ovarian research is built on mouse models that don't actually reflect human female biology, why there are only two publicly available pre-menopausal human ovary datasets not impacted by disease, and what it takes to build an AI platform grounded in real human tissue data using single-cell spatial transcriptomics. Mila also shares a 2024 Nature Aging study that reframed how the field thinks about ovarian aging entirely. It's a conversation about one of the most underfunded and under researched areas in medicine and what it looks like to fix it.
Show Notes:www.novaarchealth.com
Episode 28: The Algorithm Has a Women's Health Problem
2026/10/21
We sit down with Geri Stengel, Forbes contributor, founder of Ventureneer, and co-chair of the Women's Health Technology Coalition, who has spent years reporting at the intersection of AI and women's health. Geri opens with a number that frames everything: from 1977 to 1993, the FDA recommended excluding women of childbearing age from clinical trials. That's nearly half of the core historical dataset that AI models are trained on.
We get into the specialized companies building clinical-grade tools on narrow, targeted women's health data, why women are actually consenting to share their data at rates of up to 97%, and a systemic problem most people haven't heard of: search engines and social media platforms are routinely flagging standard medical terms like menstruation and menopause as adult content. That suppression drives up acquisition costs, distorts fundraising, and ultimately widens the health disparity gap. It's one of the more eye-opening conversations we've had on the show.
Show notes:
https://ventureneer.com/https://www.forbes.com/sites/geristengel/https://geristengel.substack.com/
Episode 27: The Memory Code AI Is Starting to Crack
2026/10/14
For this episode, we sit down with Kristeen Pareja-Navarro, co-CEO of Engram Bio, whose path from a farming family in the Philippines to peptide engineering for Alzheimer's disease at the Buck Institute is one of the more remarkable stories we've heard on the show. Kristeen walks us through her work trimming the KIBRA protein into a small functional peptide that rescues memory impairment in mice, and how tools like AlphaFold 3 and ESMFold have compressed years of structural biology work into days.
But she's equally candid about where AI falls short. Intrinsically disordered proteins still break the models. AI summaries miss the nuances buried in figures and methods. And no amount of compute can answer the question the field is still wrestling with: how does memory persist when every cell in your body eventually turns over. A grounded, honest conversation about what AI is genuinely changing in early-stage drug development and what it isn't.
Show Notes:
https://www.biorxiv.org/content/10.64898/2026.06.03.729735v1.full.pdfhttps://www.nature.com/articles/s41586-025-09429-6
Episode 26: Bigger Models Won't Save Biomanufacturing
2026/10/07
We sit down with Shawn Manchester, CEO of TripleBar, whose path from yeast DNA repair to metabolic engineering at MIT to biomanufacturing AI gave him a front-row seat to one of biotech's most underappreciated problems.
Everyone funds discovery. Nobody funds manufacturing. And yet a molecule that can't be made reliably and cheaply at scale never reaches a patient. Shawn makes the case that biomanufacturing is where the real bottleneck lives, and why it's finally getting the AI attention it deserves. It's a refreshingly grounded conversation about what biological AI actually requires to work.
Episode 25: The 200-Page Protocol Problem AI Is Finally Solving
2026/09/30
In this episode of From Models to Medicine, we sit down with Angie Schwab, CEO and founder of Trialynx, who has spent 20 years watching clinical trials run over budget, over timeline, and over complexity for one reason: nobody got rid of the copy-paste. Angie makes a sharp distinction that most people in the AI conversation are blurring. That automation and AI are not the same thing, and deploying generative AI on top of unstructured workflows without fixing the foundation first is how you get polished-looking documents that still require someone to fact-check every line.
We get into how Trialynx compresses months of protocol documentation into 30 days, why a single source of truth changes everything downstream, and where Angie draws a hard line on what AI should never touch. The episode closes on a genuinely provocative idea: AI pseudo-clinical trials that run molecules through synthetic models of human biology before a single patient is enrolled.
Episode 24: Beyond Correlation - Teaching AI the Rules of Biology
2026/09/16
This week, we sit down with Jean-Baptiste Morlot of Deep Life, who makes the case that the drug discovery field has been asking the wrong thing of its AI models. Correlation-based machine learning can find patterns, but it can't tell you why a cell is sick or what it would take to make it healthy again. Jean-Baptiste walks us through how single-cell sequencing unlocked the data volume needed to train something far more ambitious: a causal world model of cellular biology that learns the underlying rules of disease rather than memorizing them.
We get into how Deep Life's TwinCell platform works, why most virtual cell benchmarks are quietly inflated by popularity bias, and what it means to build an interpretable AI that a biologist can trust.
Episode 23: When Biologists Start Thinking Like Engineers
2026/09/02
This week, we sit down with Katie Lennon, CSO of Exthymic, who makes a case most bench scientists aren't ready to hear: biology isn't just a discovery discipline anymore. It's engineering. Katie walks us through what it actually looks like to build biology, hardware, and software concurrently, why that requires a shared language across disciplines, and what gets lost when teams hand off instead of collaborate.
We also get into the unglamorous side of AI in the lab. More data documentation, peer-checking metadata before an experiment is marked complete, and knowing exactly where LLMs quietly get things wrong. Katie also shares a surprisingly effective strategy for getting scientists over their fear of AI tools.
Companies mentioned in the show:
https://exthymic.com/https://oni.bio/https://www.potato.ai/https://ollie.ai/
-------------------
Sign up for KAMI Think Tank's Maven course here! Classes start in less than 10 days!!
Episode 22: The Model Was Never Built for Her
2026/08/26
In this episode of From Models to Medicine, we sit down with Mark Amouzgar, co-founder and CEO of March Health. Mark opens with a striking stat: general-purpose AI models are only about 60% accurate in women's health. Sounding confident isn't the same as being clinically safe, and in this episode he breaks down exactly why generic AI was never built for this.
We get into how March Health built a gender-aware digital twin, what it takes to wrap a model in real clinical logic, and why the average endometriosis patient sees eight different doctors before getting an accurate diagnosis. It's a candid conversation about a problem that doesn't get nearly enough attention.
-------------------------
Sign up for KAMI Think Tank's Maven course here!
Episode 21: Glass Box Wins - What Pharma Actually Trusts in AI
2026/08/19
In this episode of From Models to Medicine, we sit down with Lavanya Anandan, Head of External Innovation, West Coast at CSL, whose path from bench scientist to Merck Group platform builder to UCSF Innovation Venture startup advisor gives her a rare view of where AI in drug discovery is delivering versus where it's mostly promise. She makes a sharp case that the companies winning in AI-bio aren't necessarily the ones with the best models, and the reason why might surprise you.
We get into what big pharma wants from an AI partner, why women's health data scarcity is quietly producing some of the most rigorous AI in biology, and what an unexpected finding in mRNA research tells us about where this whole field might be heading.
Articles mentioned in show: https://endpoints.news/can-ai-do-scientific-research-billions-chase-hopes-of-superintelligence/
Maven course: https://maven.com/kamithinktank/ai-literacy-for-life-sciences-healthcare
Episode 20: The Build vs. Buy Question Every Pharma Leader is Wrestling With
2026/08/12
We chat with Karl Moritz, CEO of Reliant AI, now part of Cohere, whose career took him from NLP research to McKinsey to building AI infrastructure for drug development. Karl reminds us that clinical trial success rates have been stuck years, and the golden age of AI-powered target discovery isn't fixing it.
Karl lays out a sharp framework; own the science, rent the AI plumbing, and explains why building your own data ingestion pipeline is as misguided as writing your own operating system. He's also candid about what general-purpose LLMs are actually good for, where purpose-built enterprise tools earn their keep, and why the audit trail question will separate serious AI vendors from everyone else. If you're a pharma or biotech leader trying to make sense of the build vs. buy debate right now, this one is worth your time.
Episode 19: Flow Cytometry, Biomarkers, and the AI Patterns Nobody Is Verifying
2026/08/05
For this episode, we sit down with Banishree Saha, Global Biomarkers Lead at Takeda, who has worked in fields such as academic liver biology to translational biomarker work, over the course of her 20-year career. She walks us through what biomarkers really are, how flow cytometry went from single-color panels to capturing 40 proteins simultaneously, and why that explosion in data has made systems thinking the only way forward.
Banishree talks about AI's strengths and weaknesses, and makes the case that the scientists most at risk from AI aren't the ones who know too much biology. But are the ones who don't know enough to catch when the model is wrong.
Episode 18: Why Does mRNA Keep Breaking AI Models?
2026/07/29
In this episode, we sit down with Chris Nelson, an mRNA scientist at nCode Bio whose career has taken him from building blood transfusion matching tests now used by the NHS, to cancer genomics at Personalis, to the frontier of mRNA sequence design. Chris breaks down why the untranslated regions of mRNA might actually change how we dose therapeutics, reduce side effects, and engineer cells inside the body entirely.
Then we talk about why AI has conquered protein folding but keeps hitting a wall with mRNA. Chris walks us through the data problem, the cost problem, and the modeling choices nCode Bio is making that go against the grain of what most of the field is building. He's also candid about where the big model providers are letting biology down and which scrappy research groups he thinks are quietly building the tools that will actually matter.
Episode 17: Garbage Data, Toxic Exposure, and the AI Gap in Environmental Health
2026/07/22
In this episode of From Models to Medicine, we sit down with Sarah Daniels, an environmental health researcher, who makes the argument that the chemicals making us sick might also be our best clues for building better drugs. She traces that idea from a 1976 discovery about dioxins all the way to an FDA-approved psoriasis treatment in 2023 — and asks what AI could accelerate if the field finally got its data act together.
Sarah brings up where AI in environmental health is genuinely stuck; siloed industry data, models built only for acute toxicity, and a chronic low-dose problem that no one has cracked. She also shares how she used APIs to build her own real-time funding tracker for microplastics research in under a month, and why the gap between what AI promises and what environmental health can actually feed it is one of the most under appreciated bottlenecks in the field right now.
Links mentioned in this episode:
Historic ARPA-H program funding announcement on Microplastics: https://arpa-h.gov/explore-funding/programs/stompSarah's two cents on the ARPA-H Microplastics program: https://engineeredresilience.substack.com/p/a-microplastics-prelude-for-engineeredAggregated trends in microplastics from the non-peer-reviewed literature (Trendspotter App):https://www.engineeredresilience.org/microplasticsStay up to date on latest releases from Sarah's work on Engineered Resilience by signing up for substack: https://engineeredresilience.substack.com/Report on unexpected health effects observed after LA fires showing how questions remain post-exposure to pollutants:https://www.latimes.com/environment/story/2025-12-17/la-fires-heart-attacks-strange-blood-test-results-spikedCan a Biologist Fix a Radio? - great piece on the necessity to understand biology at the systems-level: https://www.cell.com/cancer-cell/fulltext/S1535-6108(02)00133-2
Episode 16: Why Chemistry has Held Drug Discovery Back
2026/07/15
Stan Jastrzębski is the co-founder of molecule.one and a deep learning researcher who made a deliberate pivot into synthetic chemistry. In this episode, he explains why chemistry is the real bottleneck in drug discovery today. Unlike biology, which has the Protein Data Bank and tools like AlphaFold, chemistry lacks the massive, balanced datasets AI needs to work. Scientific literature makes it worse, publishing wins and burying failures, which starves models of exactly the negative data they learn from most.
Stan also talks about "vibe binding," the industry's growing tendency to over-rely on biological binding models that only work on well-trodden targets and quietly kill scientific creativity in the process. He closes with a sharp take on where LLMs actually hit their ceiling, and why he thinks scientific discovery is not just a use case for AI but its ultimate test.
Episode 15: Stacking AI with Quantum in the Sciences
2026/07/08
Anna Benefiel has spent over 20 years in healthcare innovation, and she's tired of watching life sciences sit on the sidelines of quantum computing. In this episode, she makes a direct case for why pharma needs to stop treating quantum as a future problem and start treating it as a present opportunity. We get into what quantum actually does that classical computing cannot, why probabilistic nuance matters for complex biological problems, and where the real near-term value lives: clinical trial optimization, supply chain, and cell culture yields.
We also dig into what happens when you stack quantum on top of AI. Anna points to models already using standard histopathology slides to generate spatial proteomic maps for lung cancer, and argues quantum is what takes discoveries like that to the next order of magnitude.
*The views represented on this podcast are not a reflection of Strangeworks.
Podcast reviews
Read From Models to Medicine podcast reviews
markppan 2026/09/18
5 stars from not an AI bot
Could listen to this all day
Michelle Y. Y. 2026/07/13
Not just promoting AI products
What I really enjoy about this podcast is how it actually highlights scientists’ and founders’ real journeys with AI in the field. It’s hard to parse ...
M L Rivers 2026/05/27
Timely!
This is excellent, timely content from two very skilled moderators. Great work!
Podcast sponsorship advertising
Start advertising on From Models to Medicine relevant audience podcasts
You may also like to advertise on these Podcasts

4.8224901808
The Andrew Klavan Show
The Daily Wire

4.6652782197
The Charlie Kirk Show
Charlie Kirk

4.930902000
The Quote of the Day Show | Daily Motivational Talks
Sean Croxton

4.6432911273
Verdict with Ted Cruz
Premiere Networks

4.762612000
The Lawfare Podcast
The Lawfare Institute

4.7278922000
The Matt Walsh Show
The Daily Wire

4.818422000
The Cabral Concept
Dr. Stephen Cabral

4.6314191097
Wow in the World
Tinkercast

4.8121251000
Mind Pump: Raw Fitness Truth
Sal Di Stefano, Adam Schafer, Justin Andrews, Doug Egge

4.6620122000
The Dan Bongino Show
Cumulus Podcast Network | Dan Bongino